(Q82849348)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20145610%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

title

Clinical utility of measuring infliximab and human anti-chimeric antibody concentrations in patients with inflammatory bowel disease (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20145610%20AND%20SRC:MED&resulttype=core&format=json

inflammatory bowel diseases

18 January 2020

main subject

1 reference

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20145610%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

William Jeffery Sandborn

7

object named as

William J Sandborn

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20145610%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

author name string

Waqqas Afif

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20145610%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

William A Faubion

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20145610%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

Sunanda V Kane

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20145610%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

David H Bruining

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20145610%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

Karen A Hanson

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20145610%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

publication date

9 February 2010

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20145610%20AND%20SRC:MED&resulttype=core&format=json

The American Journal of Gastroenterology

18 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20145610%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

volume

105

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20145610%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

issue

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20145610%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

page(s)

1133-1139

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20145610%20AND%20SRC:MED&resulttype=core&format=json

Immunogenicity negatively influences the outcome of adalimumab treatment in Crohn's disease

18 January 2020

cites work

1 reference

12 December 2020

Relationship between serum trough infliximab levels, pretreatment C reactive protein levels, and clinical response to infliximab treatment in patients with rheumatoid arthritis

1 reference

12 December 2020

Individualized monitoring of drug bioavailability and immunogenicity in rheumatoid arthritis patients treated with the tumor necrosis factor alpha inhibitor infliximab

1 reference

12 December 2020

Maintenance therapy with certolizumab pegol for Crohn's disease

1 reference

12 December 2020

Certolizumab pegol for the treatment of Crohn's disease

1 reference

12 December 2020

Incidence and clinical significance of immunogenicity to infliximab in Crohn's disease: a critical systematic review

1 reference

12 December 2020

Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial

1 reference

12 December 2020

Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn's disease

1 reference

12 December 2020

Infliximab dose escalation vs. initiation of adalimumab for loss of response in Crohn’s disease: a cost-effectiveness analysis

1 reference

12 December 2020

Formation of antibodies against infliximab and adalimumab strongly correlates with functional drug levels and clinical responses in rheumatoid arthritis

1 reference

12 December 2020

Clinical trial: benefits and risks of immunomodulators and maintenance infliximab for IBD-subgroup analyses across four randomized trials

1 reference

12 December 2020

Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease

1 reference

12 December 2020

Influence of Immunogenicity on the Long-Term Efficacy of Infliximab in Crohn's Disease

1 reference

12 December 2020

Human antichimeric antibody in children and young adults with inflammatory bowel disease receiving infliximab

1 reference

12 December 2020

A multicenter study of recombinant factor VIII (recombinate): safety, efficacy, and inhibitor risk in previously untreated patients with hemophilia A. The Recombinate Study Group

1 reference

12 December 2020

Tumor necrosis factor-alpha binding capacity and anti-infliximab antibodies measured by fluid-phase radioimmunoassays as predictors of clinical efficacy of infliximab in Crohn's disease

1 reference

12 December 2020

Withdrawal of immunosuppression in Crohn's disease treated with scheduled infliximab maintenance: a randomized trial

1 reference

12 December 2020

Optimizing anti-TNF treatment in inflammatory bowel disease

1 reference

12 December 2020

Natalizumab Induction and Maintenance Therapy for Crohn's Disease

1 reference

12 December 2020

Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial

1 reference

12 December 2020

Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial

1 reference

12 December 2020

A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group.

1 reference

12 December 2020

Natalizumab for the treatment of active Crohn's disease: results of the ENCORE Trial

1 reference

12 December 2020

Infliximab for induction and maintenance therapy for ulcerative colitis

1 reference

12 December 2020

Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis

1 reference

12 December 2020

Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn's disease: a randomized controlled trial

1 reference

12 December 2020

Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial.

1 reference

12 December 2020

Immunogenicity of recombinant DNA human insulin

1 reference

12 December 2020

Monitoring patients treated with anti-TNF-alpha biopharmaceuticals: assessing serum infliximab and anti-infliximab antibodies

1 reference

12 December 2020

Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn's disease

1 reference

12 December 2020

Identifiers

DOI

10.1038/AJG.2010.9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20145610%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20145610%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

PubMed publication ID

20145610

1 reference